scholarly journals The British National Formulary : past, present and future

Prescriber ◽  
2017 ◽  
Vol 28 (12) ◽  
pp. 20-24 ◽  
Author(s):  
Joy Ogden
Keyword(s):  
British National Formulary ◽  
National Formulary

Abbreviating grams

1969 ◽  
Vol 7 (7) ◽  
pp. 28-28
Keyword(s):  
The Other ◽  
British National Formulary ◽  
Scientific Journals ◽  
National Formulary ◽  
British Pharmacopoeia

The internationally accepted abbreviation for gram used in all scientific journals is ‘g’, but the British Pharmacopoeia and the British National Formulary have for many years recommended that ‘G’ (internationally used to abbreviate Gauss) be used for writing prescriptions. This usage was introduced to prevent confusion between the handwritten abbreviations for grams and grains which occasionally led to serious overdosage. This month the use of grains and the other ‘imperial’ measures in dispensing and labelling finally ceased, and with it the need to write ‘G’ for gram. This Bulletin will from now on use ‘g’ for grams.

Rhinological, laryngological, oropharyngeal and other head and neck side effects of drugs

2006 ◽  
Vol 120 (2) ◽  
pp. 1-10 ◽  
Author(s):  
C A Lee ◽  
D Mistry ◽  
R Sharma ◽  
A P Coatesworth
Keyword(s):  
Hearing Loss ◽  
Drug Therapy ◽  
Side Effects ◽  
Head And Neck ◽  
British National Formulary ◽  
National Formulary ◽  
Drug Side Effects

Following a previous paper in which we documented the otological side effects of drug therapy, we here review other drug side effects that ENT surgeons may encounter when dealing with patients. Although otological drug side effects such as hearing loss and tinnitus are well recognized there are many rhinological, laryngeal, oropharyngeal and other head and neck drug side effects. Our data were sourced from the British National Formulary and Electronic Medical Compendium websites.

Antivenom for adder-bites

1976 ◽  
Vol 14 (22) ◽  
pp. 87-88
Keyword(s):  
British National Formulary ◽  
National Formulary ◽  
Pasteur Institute

When we last wrote about the treatment of adder-bites1 we doubted the value of the antivenom then available (Antiviperin ER - Pasteur Institute) and this treatment has now disappeared from the British National Formulary. However the Zagreb antivenom (Regent Laboratories) introduced into the U.K. in 1969, is claimed to have important advantages.

Terminal care: ‘drug control of common symptoms’

1986 ◽  
Vol 24 (22) ◽  
pp. 88.3-88
Keyword(s):  
General Practice ◽  
Terminal Care ◽  
British National Formulary ◽  
Drug Control ◽  
National Formulary

The first edition of this pamphlet compiled by Dr. Mary Baines from St. Christopher’s Hospice, London was published in 1981. They now have a much revised third edition (A4, 8 pages). It amplifies the section on terminal care in the British National Formulary (BNF 12, p8) and will especially help doctors with relatively little experience in this field, whether in general practice or in hospital.

Which insulin?

1982 ◽  
Vol 20 (23) ◽  
pp. 89-92
Keyword(s):  
Physical State ◽  
British National Formulary ◽  
National Formulary ◽  
Duration Of Action ◽  
Speed Of Onset

The British National Formulary lists 27 insulin preparations1 which now include the first of the new ‘human’ insulins. The insulins differ in their structure, purity, potency, pH and physical state. These affect the speed of onset and duration of action of the different preparations and also help explain the variations in response that may occur in any one patient and between different patients. The profusion of preparations means that it is no longer possible to have a thorough working knowledge of each formulation. In this article we discuss the differences and suggest ways of simplifying the choice.

How to use the British National Formulary

BMJ ◽  
2001 ◽  
Vol 323 (Suppl S1) ◽  
pp. 0107228
Author(s):  
Oliver Jones
Keyword(s):  
British National Formulary ◽  
National Formulary

Therapy-related issues: malignant diseases and immunosuppression

2017 ◽  
Author(s):  
Philip Wiffen ◽  
Marc Mitchell ◽  
Melanie Snelling ◽  
Nicola Stoner
Keyword(s):  
Malignant Disease ◽  
Intrathecal Administration ◽  
Cytotoxic Drugs ◽  
Nausea And Vomiting ◽  
British National Formulary ◽  
National Formulary ◽  
Malignant Diseases ◽  
Clinical Screening ◽  
Clinical Pharmacists

This chapter outlines information relevant to clinical pharmacists related to malignant disease and immunosuppression and is loosely based on the British National Formulary, Chapter 8. In particular, this chapter covers administration and handling of cytotoxic drugs, clinical screening of chemotherapy prescriptions, chemotherapy dosing and toxicity, antiemetics for chemotherapy-induced nausea and vomiting, extravasation, and intrathecal administration of chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document